Placeholder

Ropinirole

  • # LGM Pharma is a Ropinirole CAS# 91374-21-9 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Ropinirole
  • CAS #: 91374-21-9
  • Mode of Action:

    Ropinirole binds the dopamine receptors D_ and D_. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

  • Pharmacodynamics:

    Ropinirole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The mechanism of ropinirole-induced postural hypotension is presumed to be due to a D2 -mediated blunting of the noradrenergic response to standing and subsequent decrease in peripheral vascular resistance.

  • Metabolism:

    Hepatic. Ropinirole is extensively metabolized to inactive metabolites via N -despropylation and hydroxylation pathways, largely by the P450 isoenzyme CYP1A2. N-despropyl ropinirole is the predominant metabolite found in urine (40%), followed by the carboxylic acid metabolite (10%), and the glucuronide of the hydroxy metabolite (10%).

  • Toxicity:

    Symptoms of overdose include agitation, chest pain, confusion, drowsiness, facial muscle movements, grogginess, increased jerkiness of movement, symptoms of low blood pressure (dizziness, light-headedness)upon standing, nausea, and vomiting.

  • IUPAC: 4-[2-(dipropylamino)ethyl]-2, 3-dihydro-1H-indol-2-one
  • ATC: N04BC04
  • PubChem: 5095
  • DrugBank: DB00268 (APRD00302)
  • Formula: C22H28FN3O6S
  • Molecular Mass: 260.3746
  • Synonyms: Ropinirol [INN-Spanish] Ropinirole HCl Ropinirole hydrochloride Ropinirolum [INN-Latin]
  • SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
  • AHFS Code: 28:36.20.08
  • InChl: UHSKFQJFRQCDBE-UHFFFAOYSA-N
  • General Reference:
    1. Ray Chaudhuri K, Martinez-Martin P, Rolfe KA, et al. Improvements in nocturnal symptoms with Ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012;19(1):105-13.
    2. Neuropsychiatr Dis Treat. 2014 May 7;10:767-76. doi: 10.2147/NDT.S60061. eCollection 2014.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service